Anti-HIV I–II

The Anti-HIV I-II test detects antibodies against HIV-1 and HIV-2 and, when necessary, the p24 antigen, thereby determining the presence of infection. It is a fundamental screening method for early diagnosis and evaluation of transmissibility and is confirmed by verification tests.

Anti-HIV antibody screening plays a critical role in the detection of acute infection. Analyses performed with highly sensitive methods provide early positivity during the seroconversion period, increasing the reliability of the diagnostic process and guiding clinical follow-up planning.

Risk-based Anti-HIV assessment includes regular testing in individuals with a high likelihood of exposure. For healthcare workers, people with a history of unprotected contact, and individuals in high-risk behavior groups, testing facilitates early intervention and access to treatment.

Population-based Anti-HIV screenings are important for controlling chains of transmission and strengthening epidemiological surveillance. Large-scale screenings contribute to mapping the spread of infection, developing prevention strategies, and optimizing public health programs.

What Is Anti–HIV I–II?

The Anti-HIV I–II test is a blood test performed to detect antibodies formed in the body against HIV (Human Immunodeficiency Virus) type 1 and type 2. It is used for the screening and diagnosis of HIV infection. It shows the presence of antibodies produced by the immune system after exposure to the virus. If the test is positive, further confirmatory tests are performed. It is critically important for early diagnosis, treatment, and prevention of transmission.

Why Are Today’s Anti-HIV Tests (4th Generation) Better?

The tests we use in medicine are constantly evolving. When we say “Anti-HIV” today, we usually mean “4th Generation Combination Tests”. The greatest advantage of these tests over older tests is that they can detect infection at a much earlier stage.

Older tests used to look only for “antibodies”. However, it takes time for the body to produce antibodies against a virus; this period can sometimes take up to 3 months. Fourth-generation tests, on the other hand, look simultaneously for both antibodies and a structural component of the virus called the “p24 antigen”. The p24 antigen can be detected in the blood very shortly after infection, even before antibodies have appeared.

This provides a major advantage during the critical period known as the “window period”. The window period is the time between the virus entering the body and the point at which the test can detect it. With tests that detect only antibodies, this period can be as long as 90 days, whereas 4th generation tests reduce this period to approximately 18 to 45 days.

IVF treatment is a race against time and is a process that is emotionally and financially very significant. When starting this journey, being able to know whether an infection is present within a short period such as 18–45 days, instead of waiting for weeks, prevents delays in treatment and ensures the highest possible level of safety for everyone.

What Should I Do If My Anti-HIV Test Result Is “Positive” (Reactive)?

This is the question that our patients worry about the most and ask most frequently. The first and most important point is this: A “positive” or “reactive” result in a screening test does not, by itself, establish a “diagnosis of HIV”. It only means that a “signal” has been detected, and this signal must definitely be confirmed by more specific follow-up tests.

Sometimes tests can give a “false positive” signal due to reasons other than HIV (for example, certain past infections, autoimmune diseases, or even pregnancy). Therefore, when a first test is positive, one should never panic and must wait for the verification algorithm to be completed.

The steps followed in this algorithm are:

• Step 1: Screening Test (usually 4th Generation Antigen/Antibody Test)
• Step 2: Confirmation Test (HIV-1/HIV-2 Antibody Differentiation Test)
• Step 3: Resolution Test (if necessary, NAT/PCR)

If the initial screening test (Step 1) is positive, Step 2 is performed immediately from the same blood sample. If the confirmation test is also positive, then the diagnosis is established.

Sometimes we encounter a clinically important situation: The first test (4th generation) is positive, but the confirmation (antibody) test is negative or “indeterminate”. This suggests either that the first test was a false positive or that the person is in the very early “acute infection” period. In this period, the body has not yet produced antibodies, but the p24 antigen (the virus itself) in the blood is detected by the test. To clarify this confusing situation, we move on to Step 3: the “Nucleic Acid Test (NAT)” or PCR, which is the most sensitive test that looks directly for the genetic material (RNA) of the virus. If NAT is positive, this means a diagnosis of acute infection.

How Does an HIV Diagnosis Affect Fertility and Reproductive Health?

HIV is a virus that can affect not only general health but also the reproductive potential of both women and men directly or indirectly.

What Are the Effects of HIV on Fertility in Women?

HIV creates a state of continuous immune activation and inflammation in the body. If the virus is not well controlled, this can disrupt the delicate hormonal balance of the brain–ovary axis (the hypothalamic–pituitary–ovarian axis), which regulates ovulation. As a result, menstrual irregularities and ovulation problems may occur.

However, perhaps the most important effect on female fertility occurs indirectly. In HIV-positive women, the risk of other sexually transmitted infections (such as Chlamydia and Gonorrhea) is higher. These infections may lead to Pelvic Inflammatory Disease (PID), which causes damage, adhesions, and blockage (hydrosalpinx) in the fallopian tubes. Blocked tubes prevent sperm from reaching the egg naturally. This condition is known as “tubal factor infertility” and typically requires IVF treatment.

What Are the Effects of HIV on Fertility in Men?

The virus can also target the male reproductive system. It may directly cause inflammation in the testes (orchitis) and damage the delicate tissue where sperm production occurs. This can impair the process of spermatogenesis.

As a result, in semen analyses (spermiograms) of HIV-positive men, we more frequently encounter certain abnormalities:

• Decreased sperm count (oligospermia)
• Reduced sperm motility (asthenozoospermia)
• Decreased proportion of morphologically normal sperm (teratozoospermia)
• Decreased semen volume

Therefore, even if the problem seems to be only on the female side in a couple who wish to have a child, it is very important to perform a detailed semen analysis if the male partner is known to be HIV positive and not to overlook a potential “male factor”.

Do HIV Medications (ART) Affect Sperm Quality?

This is one of the main issues we consider when planning IVF treatment. Antiretroviral therapy (ART), the medications used to treat HIV, is vital to suppress the virus and allow the person to live a healthy life. These medications must never be discontinued.

However, some of these life-saving drugs can have undesirable effects on reproductive cells. Sperm cells are particularly sensitive to such effects. It is known that some medications can have a toxic effect on “mitochondria”, the energy powerhouses that produce the energy sperm need to move.

Clinically, the most important consequence of this is “sperm DNA fragmentation” (SDF), meaning that breaks occur in the genetic material (DNA) carried in the head of the sperm. High levels of DNA damage reduce the sperm’s ability to fertilize the egg; even if fertilization occurs, embryo quality may be compromised and pregnancy loss (miscarriage) may result.

This is exactly where modern IVF techniques come into play. Even if sperm motility is reduced or the risk of DNA damage is high, the “Intracytoplasmic Sperm Injection (ICSI)” method allows a single healthy sperm selected in the laboratory to be injected directly into the egg. ICSI is the most powerful treatment option that enables us to bypass the negative effects of these medications on sperm and the risk of fertilization failure.

What Is the Most Important Rule HIV-Positive Individuals Should Know Before Having a Baby?

On the journey to becoming parents, the most important, non-negotiable goal is to reduce and maintain the viral load of the HIV-positive partner (or partners) at an “Undetectable” level.

Viral load indicates the amount of virus in 1 milliliter of blood. “Undetectable Viral Load” (UVL) means that the person is using their treatment properly and that the amount of virus in the blood has fallen below the lower limit that tests can detect (usually 20–50 copies/mL).

This has led to the game-changing “U=U” (Undetectable = Untransmittable) principle of modern HIV treatment. It has been clearly demonstrated in scientific studies that a person whose viral load has been undetectable for at least six months has ZERO risk of transmitting the virus sexually to their partner.

For this reason, before any IVF treatment or natural attempts at conception, it is a “golden rule” that the HIV-positive partner must have been on stable ART for at least 6 months and that their viral load is confirmed to be undetectable by tests.

Benefits of achieving an undetectable viral load:

• Protects the person’s own immune system and overall health
• Prevents sexual (horizontal) transmission to the partner
• Prevents transmission from mother to baby (vertical transmission) during pregnancy

In the past, if one partner was HIV negative (a serodiscordant couple), it was recommended that the negative partner use a preventive medication called “PrEP” for protection. However, due to the U=U principle, if the positive partner’s viral load is already undetectable, this is no longer a medical necessity but rather an optional additional safety layer that the couple may choose to feel more secure.

Which IVF Methods Are Used in the Presence of HIV?

The presence of HIV does not prevent couples from becoming parents; it simply determines which protocol and which laboratory technique will be used. The method to be applied depends on which partner is HIV positive.

• If the male partner is HIV positive:

This scenario requires the most careful laboratory intervention to prevent transmission of the virus to the mother or the embryo.

The prerequisite is that the man’s viral load is at an “undetectable” (U=U) level.

The semen sample obtained from the man is not used directly. It is first processed in the andrology laboratory using a special procedure called “sperm washing”. With this procedure, healthy sperm are completely separated from the semen fluid and other cells where the virus may be present.

These clean and healthy sperm are then injected directly into the eggs retrieved from the female partner using the “Intracytoplasmic Sperm Injection (ICSI)” method.

ICSI serves two purposes here: First, by selecting a single sperm that has been separated from all surrounding fluid, it provides one last safety step that reduces the theoretical transmission risk to zero. Second, it helps overcome potential negative effects of HIV and ART medications on sperm quality (reduced motility, DNA damage) and ensures fertilization.

The safety record of this protocol is excellent; when applied correctly, no cases of virus transmission from father to mother or baby have been reported.

• If the female partner is HIV positive:

Thanks to the U=U principle, this scenario is much simpler.

The sole and absolute requirement is that the woman’s viral load is at an “undetectable” (U=U) level before pregnancy and remains so throughout pregnancy.

If the woman’s viral load is undetectable and there is no other cause of infertility in the couple (such as tubal blockage or sperm problems), the risk of sexual transmission to the male partner is zero according to the U=U principle. These couples can safely attempt conception “naturally”.

IVF treatment is used only if there is another underlying cause of infertility (for example, tubal blockage due to HIV-associated PID or advanced maternal age). In this case, the laboratory process is no different from standard IVF.

• If both partners are HIV positive:

The goal is to ensure that both partners’ viral loads are at undetectable levels. In the laboratory, potential sperm quality issues in the male partner (due to HIV and ART) are taken into account. To maximize pregnancy chances, even though there is no transmission risk between the partners, the most efficient fertilization method, “Intracytoplasmic Sperm Injection (ICSI)”, is usually recommended as the first choice.

What Is “Sperm Washing” and How Does It Eliminate HIV Risk?

“Sperm washing” is a high-technology laboratory procedure used when the male partner is HIV positive. The underlying principle is this: HIV does not reside inside healthy, motile sperm cells. Instead, the virus is primarily found free in the “seminal plasma” (semen fluid) and inside other cells such as leukocytes (white blood cells).

The sperm washing procedure is designed to separate healthy, motile sperm from this risky fluid and other cells. It is usually performed in two stages:

• First Stage: Density Gradient
• Second Stage: Swim-Up

In the first stage (density gradient), the semen sample is placed onto a liquid consisting of layers with different densities and spun at high speed (centrifuged). In this process, heavy and healthy motile sperm settle at the bottom, while semen fluid, viral particles, leukocytes, and unhealthy sperm remain in the upper layers. The upper, risky portion is discarded, and only the bottom fraction containing healthy sperm is retained.

In the second stage (swim-up), a clean culture medium is added on top of the sperm. Only the most motile and healthiest sperm actively “swim up” into the upper clean layer. Only this clean fraction is collected and used for microinjection.

This two-step filtration reduces the viral load by more than 99.99% and, when combined with ICSI, effectively reduces the risk of transmission to zero.

What Is Done to Prevent HIV Transmission During Birth and Breastfeeding?

Once pregnancy is achieved, the goal is for the baby to be born HIV negative. The most important factor in reducing the risk of mother-to-child transmission to far below 1% is continuous adherence to ART during pregnancy and maintaining the mother’s viral load at an “undetectable” level.

How Is the Mode of Delivery Determined?

In the past, cesarean section was routinely recommended for HIV-positive mothers, but this approach has completely changed. Today, the decision is based on the mother’s viral load at the time of delivery.

• If the viral load is undetectable (<50 copies/mL): Vaginal delivery is safe.
• If the viral load is high (>1000 copies/mL) or unknown: Planned cesarean section is recommended to prevent the baby from coming into contact with the virus while passing through the birth canal.

What Measures Are Taken After the Baby Is Born?

All babies born to HIV-positive mothers are given a preventive antiretroviral syrup (Post-Exposure Prophylaxis – PEP) within the first hours after birth. This is a safety measure to prevent any virus the baby may have encountered during delivery from establishing infection. Depending on the mother’s risk status (low-risk or high-risk), this prophylactic syrup is continued for 2 to 6 weeks.

Can an HIV-Positive Mother Breastfeed Her Baby?

This is one of the most sensitive issues. HIV can be transmitted to the baby through breast milk. In countries where there is safe and continuous access to clean water and formula (such as Türkiye), the standard recommendation to reduce the risk to absolute zero is “feeding with formula”.

However, modern approaches also note the following: If the mother adheres perfectly to treatment during pregnancy and breastfeeding, and her viral load remains undetectable throughout, the risk of transmission through breast milk is less than 1% (though not zero). A mother who is fully informed of and accepts this very small risk and strongly wishes to breastfeed may be supported in this decision, provided that she and her baby are monitored very closely (with frequent viral load checks). This is a “shared decision” that must always be made together with the treating physician.

How Are Eggs and Sperm of HIV-Positive Patients Stored in the Laboratory?

One of the most important responsibilities of IVF laboratories is to eliminate—even at a theoretical level—the risk of “cross-contamination”, meaning the risk that one patient’s sample might come into contact with another’s.

To achieve this, strict rules known as “Universal Precautions” are applied. According to these rules, all incoming blood, sperm, and egg samples are processed as if they were infectious.

Key laboratory safety measures for samples from HIV-positive patients include:

• Working inside dedicated, certified biological safety cabinets
• Use of full protective equipment (gloves, gown, goggles)
• Single-use, sterile materials (pipettes, tubes, dishes) for each patient
• Handling only one patient’s sample at a time during any given procedure

However, the most critical and non-negotiable rule relates to freezing and storage. All frozen sperm, eggs, and embryos belonging to patients with blood-borne infections such as HIV or hepatitis B/C are stored in special cryotanks dedicated exclusively to these samples and permanently labeled as “infectious”, completely separate from other patients’ samples. This physical separation ensures that there is no cross-contamination risk, even in liquid nitrogen. Thanks to these protocols, no cross-contamination cases have been reported in ART laboratories to date.

Frequently Asked Questions